Printer Friendly

Watson starts shipping generic LIPITOR.

M2 PHARMA-December 1, 2011-Watson starts shipping generic LIPITOR(C)2011 M2 COMMUNICATIONS

1 December 2011 - US Watson Pharmaceuticals Inc (NYSE:WPI) said on Wednesday it had launched an authorised generic version of LIPITOR (atorvastatin calcium tablets) as part of an exclusive deal with Pfizer Inc (NYSE:PFE).

LIPITOR is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL, triglycerides and to increase HDL cholesterol.

Under the exclusive supply and distribution contract, Pfizer makes and supplies Watson with all dosage strengths of the authorised generic product, while Watson markets and distributes the product in the US.

Pfizer will receive a share of the net sales from Watson's sales of the product. The agreement runs until 30 November 2016, Watson added.

For the year to September 2011, LIPITOR had sales of about USD7.8bn (EUR5.8bn), according to IMS Health data.

(USD1 = EUR0.743)

((Comments on this story may be sent to>PDDecember 1, 2011>JNM2 PHARMA.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 1, 2011
Previous Article:PolyOne forms healthcare alliance with SANITIZED AG.
Next Article:Merrimack begins patient dosing in Phase I trial of MM-121.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters